Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a

Alessio Aghemo, Maria Grazia Rumi, Sara Monico, Matteo Banderali, Antonio Russo, Francesco Ottaviani, Mauro Vigano, Roberta D'Ambrosio, Massimo Colombo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. Objectives: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. Patients and Methods: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800-1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry, otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. Results: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P <0.0001). Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P <0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. Conclusions: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.

Original languageEnglish
Pages (from-to)918-924
Number of pages7
JournalHepatitis Monthly
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Ribavirin
Salivary Glands
Interferons
Hepatitis
Xerostomia
Therapeutics
peginterferon alfa-2a
Withholding Treatment
Chronic Hepatitis B
Chronic Hepatitis C
Hepatitis C

Keywords

  • Ribavirin peginterferon alfa-2a salivary glands hepatitis C hepatitis B

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a. / Aghemo, Alessio; Rumi, Maria Grazia; Monico, Sara; Banderali, Matteo; Russo, Antonio; Ottaviani, Francesco; Vigano, Mauro; D&apos;Ambrosio, Roberta; Colombo, Massimo.

In: Hepatitis Monthly, Vol. 11, No. 11, 11.2011, p. 918-924.

Research output: Contribution to journalArticle

Aghemo, Alessio ; Rumi, Maria Grazia ; Monico, Sara ; Banderali, Matteo ; Russo, Antonio ; Ottaviani, Francesco ; Vigano, Mauro ; D&apos;Ambrosio, Roberta ; Colombo, Massimo. / Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a. In: Hepatitis Monthly. 2011 ; Vol. 11, No. 11. pp. 918-924.
@article{3bb07e87993a4098bf3a6af09c3d7db2,
title = "Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a",
abstract = "Background: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. Objectives: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. Patients and Methods: Thirty-one na{\"i}ve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800-1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry, otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. Results: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87{\%} vs. 40{\%}, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97{\%} vs. 20{\%}, P <0.0001). Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P <0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. Conclusions: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.",
keywords = "Ribavirin peginterferon alfa-2a salivary glands hepatitis C hepatitis B",
author = "Alessio Aghemo and Rumi, {Maria Grazia} and Sara Monico and Matteo Banderali and Antonio Russo and Francesco Ottaviani and Mauro Vigano and Roberta D&apos;Ambrosio and Massimo Colombo",
year = "2011",
month = "11",
doi = "10.5812/kowsar.1735143X.733",
language = "English",
volume = "11",
pages = "918--924",
journal = "Hepatitis Monthly",
issn = "1735-143X",
publisher = "Kowsar Publishing Company",
number = "11",

}

TY - JOUR

T1 - Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a

AU - Aghemo, Alessio

AU - Rumi, Maria Grazia

AU - Monico, Sara

AU - Banderali, Matteo

AU - Russo, Antonio

AU - Ottaviani, Francesco

AU - Vigano, Mauro

AU - D&apos;Ambrosio, Roberta

AU - Colombo, Massimo

PY - 2011/11

Y1 - 2011/11

N2 - Background: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. Objectives: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. Patients and Methods: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800-1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry, otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. Results: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P <0.0001). Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P <0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. Conclusions: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.

AB - Background: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. Objectives: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. Patients and Methods: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800-1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry, otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. Results: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P <0.0001). Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P <0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. Conclusions: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.

KW - Ribavirin peginterferon alfa-2a salivary glands hepatitis C hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=82955173090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955173090&partnerID=8YFLogxK

U2 - 10.5812/kowsar.1735143X.733

DO - 10.5812/kowsar.1735143X.733

M3 - Article

C2 - 22308157

AN - SCOPUS:82955173090

VL - 11

SP - 918

EP - 924

JO - Hepatitis Monthly

JF - Hepatitis Monthly

SN - 1735-143X

IS - 11

ER -